About: Impact of statin therapy on mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS) depends on ARDS severity: a prospective observational cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Impact of statin therapy on mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS) depends on ARDS severity: a prospective observational cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Impact of statin therapy on mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS) depends on ARDS severity: a prospective observational cohort study
Creator	Hinz, José Bauer, Martin Beissbarth, Tim Ghadimi, Michael Mansur, Ashham Popov, Aron Steinau, Maximilian
Source	PMC
abstract	BACKGROUND: Previous investigations have presumed a potential therapeutic effect of statin therapy in patients with acute respiratory distress syndrome (ARDS). Statins are expected to attenuate inflammation in the lungs of patients with ARDS due to their anti-inflammatory effects. Clinical investigations of the role of statin therapy have revealed contradictory results. This study aimed to investigate whether pretreatment and continuous therapy with statins in patients with sepsis-associated ARDS are associated with 28-day survival according to disease severity (mild, moderate, or severe). METHODS: Patients with sepsis-associated ARDS from the surgical intensive care were enrolled in this prospective observational investigation. ARDS was classified into three groups (mild, moderate, and severe); 28-day mortality was recorded as the primary outcome variable and organ failure was recorded as secondary outcome variable. Sequential Organ Failure Assessment scores and the requirements for organ support were evaluated throughout the observational period to assess organ failure. RESULTS: 404 patients with sepsis-associated ARDS were enrolled in this investigation. The distribution of the ARDS subgroups was 13 %, 59 %, and 28 % for mild, moderate, and severe disease, respectively. Statin therapy improved 28-day survival exclusively in the patients with severe ARDS compared with patients without statin therapy (88.5 % and 62.5 %, respectively; P = 0.0193). To exclude the effects of several confounders, we performed multivariate Cox regression analysis, which showed that statin therapy remained a significant covariate for mortality (hazard ratio, 5.46; 95 % CI, 1.38–21.70; P = 0.0156). Moreover, after carrying a propensity score-matching in the severe ARDS cohort, Kaplan-Meier survival analysis confirmed the improved 28-day survival among patients with statin therapy (P = 0.0205). Patients with severe ARDS who received statin therapy had significantly more vasopressor-free days compared with those without statin therapy (13 ± 7 and 9 ± 7, respectively; P = 0.0034), and they also required less extracorporeal membrane oxygenation (ECMO) therapy and had more ECMO-free days (18 ± 9 and 15 ± 9, respectively; P = 0.0873). CONCLUSIONS: This investigation suggests a beneficial effect of continuous statin therapy in patients with severe sepsis-associated ARDS and a history of prior statin therapy. Further study is warranted to elucidate this potential effect. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12916-015-0368-6) contains supplementary material, which is available to authorized users.
has issue date	2015-06-01(xsd:dateTime)
bibo:doi	10.1186/s12916-015-0368-6
bibo:pmid	26033076
has license	cc-by
sha1sum (hex)	45cd60e6a65b7de2f51f93266a493b42694c6dc6
schema:url	https://doi.org/10.1186/s12916-015-0368-6
resource representing a document's title	Impact of statin therapy on mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS) depends on ARDS severity: a prospective observational cohort study
has PubMed Central identifier	PMC4462111
has PubMed identifier	26033076
schema:publication	BMC Med
resource representing a document's body	covid:45cd60e6a65b7de2f51f93266a493b42694c6dc6#body_text
is schema:about of	named entity 'PATIENTS' named entity 'DUE TO' named entity 'inflammation' named entity 'investigate' named entity 'attenuate' named entity 'continuous' named entity 'mild' named entity 'Previous' named entity 'therapy' named entity 'anti-inflammatory' named entity 'statins' named entity 'sepsis' named entity 'statin' named entity 'acute respiratory distress syndrome' named entity 'ARDS' named entity 'moderate' named entity 'observational study' named entity 'statin' named entity 'Tulsa' named entity 'ARDS' named entity 'American College of Chest Physicians' named entity 'StatSoft' named entity 'statin' named entity 'sepsis' named entity 'sepsis' named entity 'statin' named entity 'Cox regression' named entity 'ICUs' named entity 'mortality risk' named entity 'mortality risk' named entity 'infection' named entity 'anamnestic' named entity 'acute lung injury' named entity 'ECMO' named entity 'statin' named entity 'inflammation' named entity 'septic shock' named entity 'statin' named entity 'sepsis' named entity 'statin' named entity 'clinical outcomes' named entity 'mortality rate' named entity 'ICU' named entity 'plateau pressure' named entity 'sepsis' named entity 'ARDS' named entity 'statin' named entity 'myocardial infarction' named entity 'statin' named entity 'ARDS' named entity 'clinical outcomes' named entity 'sepsis' named entity 'organ support' named entity 'severe sepsis' named entity 'ARDS' named entity 'central nervous' named entity 'Oklahoma' named entity 'ICCA' named entity 'inflammatory conditions' named entity 'cardiovascular' named entity 'plasma' named entity 'plasma levels' named entity 'protein' named entity 'refractory' named entity 'statin' named entity 'informed consent' named entity 'statins' named entity '28 days' named entity 'statin' named entity 'ARDS' named entity 'vasodilatation' named entity 'respiratory failure' named entity 'electronic health records' named entity 'ICU' named entity 'ARDS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software